Quanterix New Data Show That Applying A Combination Of AD-Relevant Biomarkers With p-Tau 217 Significantly Reduces The Intermediate Zone Of A Two-cutoff p-Tau 217 Test, While Preserving High Accuracy Above 90%
Portfolio Pulse from Benzinga Newsdesk
Quanterix Corporation (NASDAQ:QTRX) presented new data at the Alzheimer's Association International Conference (AAIC) showing that a combination of AD-relevant biomarkers with p-Tau 217 significantly reduces the intermediate zone of a two-cutoff p-Tau 217 test, while maintaining high accuracy above 90%. This improvement could lead to more definitive results for patients undergoing Alzheimer's disease testing.
July 29, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Quanterix Corporation presented new data at AAIC showing that a combination of AD-relevant biomarkers with p-Tau 217 significantly reduces the intermediate zone of a two-cutoff p-Tau 217 test, while maintaining high accuracy above 90%. This could lead to more definitive results for Alzheimer's disease testing.
The new data presented by Quanterix at AAIC demonstrates a significant improvement in their Alzheimer's disease testing method. By reducing the intermediate zone and maintaining high accuracy, the company is likely to see positive market reactions due to the potential for more definitive test results. This advancement could enhance the company's reputation and drive demand for their testing solutions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100